-

Agilent to Present at Jefferies and Goldman Sachs Healthcare Conferences

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the company will participate in Q&A sessions at the Jefferies and Goldman Sachs healthcare conferences. Below are details of each session.

Jefferies Global Healthcare Conference
Mike McMullen, Agilent President and CEO
Wednesday, June 7
9:00 – 9:25 a.m. ET / 6:00 – 6:25 a.m. PT

Goldman Sachs 44th Annual Global Healthcare Conference
Bob McMahon, Agilent CFO
Tuesday, June 13
1:00 – 1:40 p.m. ET / 10:00 – 10:40 a.m. PT

Those interested in listening to the live or recorded sessions can access them from the Events section of Agilent’s investor relations website. Recordings will be available for 90 days.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insight and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Investor Contact:
Parmeet Ahuja
+1 408 345 8948
parmeet_ahuja@agilent.com

Media Contact:
Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Industry:

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB
Release Versions
English

Contacts

Investor Contact:
Parmeet Ahuja
+1 408 345 8948
parmeet_ahuja@agilent.com

Media Contact:
Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Social Media Profiles
Agilent on LinkedIn
More News From Agilent Technologies Inc.

Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company’s products, operations, and customer workflows. “AI is a top priority, and this partnership reflects both our ambition and our execution commitment — to build the enduring capability, operating model, and capacity required to consistently deliver AI‑driven innovation...

Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment...

Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally connect scientific workflows from method design through execution at the bench. OpenLab Sync extends Agilent’s OpenLab laboratory informatics portfolio beyond traditional data and sample management, enabling guided, standardized, and traceable execution of laboratory work in regulated environments. As...
Back to Newsroom